Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.57
SQNM's Cash to Debt is ranked lower than
86% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. SQNM: 0.57 )
Ranked among companies with meaningful Cash to Debt only.
SQNM' s Cash to Debt Range Over the Past 10 Years
Min: 0.48  Med: 5.37 Max: No Debt
Current: 0.57
Equity to Asset -0.32
SQNM's Equity to Asset is ranked lower than
96% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. SQNM: -0.32 )
Ranked among companies with meaningful Equity to Asset only.
SQNM' s Equity to Asset Range Over the Past 10 Years
Min: -0.32  Med: 0.67 Max: 0.87
Current: -0.32
-0.32
0.87
F-Score: 3
Z-Score: -10.12
M-Score: -3.48
WACC vs ROIC
5.04%
-120.33%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -22.51
SQNM's Operating margin (%) is ranked higher than
59% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. SQNM: -22.51 )
Ranked among companies with meaningful Operating margin (%) only.
SQNM' s Operating margin (%) Range Over the Past 10 Years
Min: -255  Med: -79.03 Max: -6.14
Current: -22.51
-255
-6.14
Net-margin (%) -12.73
SQNM's Net-margin (%) is ranked higher than
63% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. SQNM: -12.73 )
Ranked among companies with meaningful Net-margin (%) only.
SQNM' s Net-margin (%) Range Over the Past 10 Years
Min: -254.63  Med: -79.89 Max: 0.67
Current: -12.73
-254.63
0.67
ROA (%) -11.82
SQNM's ROA (%) is ranked higher than
63% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. SQNM: -11.82 )
Ranked among companies with meaningful ROA (%) only.
SQNM' s ROA (%) Range Over the Past 10 Years
Min: -92.63  Med: -50.90 Max: 0.66
Current: -11.82
-92.63
0.66
ROC (Joel Greenblatt) (%) -230.13
SQNM's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. SQNM: -230.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SQNM' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -895.1  Med: -369.48 Max: -62.87
Current: -230.13
-895.1
-62.87
Revenue Growth (3Y)(%) 11.20
SQNM's Revenue Growth (3Y)(%) is ranked higher than
62% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. SQNM: 11.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SQNM' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -20.7  Med: -14.00 Max: 296.4
Current: 11.2
-20.7
296.4
EPS Growth (3Y)(%) -48.60
SQNM's EPS Growth (3Y)(%) is ranked lower than
90% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. SQNM: -48.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SQNM' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -59.3  Med: -25.40 Max: 43.9
Current: -48.6
-59.3
43.9
» SQNM's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

SQNM Guru Trades in Q4 2014

Jim Simons 34,240 sh (New)
» More
Q1 2015

SQNM Guru Trades in Q1 2015

Jim Simons 89,700 sh (+161.97%)
» More
Q2 2015

SQNM Guru Trades in Q2 2015

Jim Simons 388,400 sh (+333.00%)
» More
Q3 2015

SQNM Guru Trades in Q3 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SQNM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 1.25
SQNM's P/S is ranked higher than
93% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. SQNM: 1.25 )
Ranked among companies with meaningful P/S only.
SQNM' s P/S Range Over the Past 10 Years
Min: 0.99  Med: 5.35 Max: 28.11
Current: 1.25
0.99
28.11
Current Ratio 4.14
SQNM's Current Ratio is ranked lower than
54% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. SQNM: 4.14 )
Ranked among companies with meaningful Current Ratio only.
SQNM' s Current Ratio Range Over the Past 10 Years
Min: 1.52  Med: 3.90 Max: 10.63
Current: 4.14
1.52
10.63
Quick Ratio 4.03
SQNM's Quick Ratio is ranked lower than
53% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. SQNM: 4.03 )
Ranked among companies with meaningful Quick Ratio only.
SQNM' s Quick Ratio Range Over the Past 10 Years
Min: 1.12  Med: 3.66 Max: 10.63
Current: 4.03
1.12
10.63
Days Inventory 23.76
SQNM's Days Inventory is ranked higher than
87% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. SQNM: 23.76 )
Ranked among companies with meaningful Days Inventory only.
SQNM' s Days Inventory Range Over the Past 10 Years
Min: 24.35  Med: 85.76 Max: 229.88
Current: 23.76
24.35
229.88
Days Sales Outstanding 18.27
SQNM's Days Sales Outstanding is ranked higher than
85% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. SQNM: 18.27 )
Ranked among companies with meaningful Days Sales Outstanding only.
SQNM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.73  Med: 49.34 Max: 97.54
Current: 18.27
5.73
97.54
Days Payable 28.53
SQNM's Days Payable is ranked lower than
72% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. SQNM: 28.53 )
Ranked among companies with meaningful Days Payable only.
SQNM' s Days Payable Range Over the Past 10 Years
Min: 26.62  Med: 115.72 Max: 169.77
Current: 28.53
26.62
169.77

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.23
SQNM's Price/Median PS Value is ranked higher than
92% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. SQNM: 0.23 )
Ranked among companies with meaningful Price/Median PS Value only.
SQNM' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.26  Med: 1.02 Max: 5.76
Current: 0.23
0.26
5.76
Price/Graham Number 1.01
SQNM's Price/Graham Number is ranked higher than
74% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. SQNM: 1.01 )
Ranked among companies with meaningful Price/Graham Number only.
SQNM' s Price/Graham Number Range Over the Past 10 Years
Min: 0.71  Med: 1.34 Max: 3.36
Current: 1.01
0.71
3.36
Earnings Yield (Greenblatt) (%) -13.70
SQNM's Earnings Yield (Greenblatt) (%) is ranked lower than
62% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. SQNM: -13.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SQNM' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -13.7  Med: 0.50 Max: 6690.1
Current: -13.7
-13.7
6690.1

More Statistics

Revenue(Mil) $128
EPS $ -0.15
Beta0.44
Short Percentage of Float15.31%
52-Week Range $1.10 - 4.80
Shares Outstanding(Mil)119.19

Analyst Estimate

Dec16 Dec17
Revenue(Mil) 122 125
EPS($) -0.29 -0.31
EPS without NRI($) -0.29 -0.31

Business Description

Industry: Biotechnology » Biotechnology
Compare:AMEX:AMPE, LSE:TRX, NAS:CYTR, AMEX:NAVB, XKRX:041910, NAS:PETX » details
Traded in other countries:QNMA.Germany,
Sequenom Inc was incorporated in 1994 under the laws of the State of Delaware. It is a life sciences company providing revolutionary genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets. It develop and commercialize molecular diagnostics testing services that target and serve molecular diagnostics markets, and also develop and commercialize research use genetic analysis products and services that target and serve discovery and clinical research markets. It offers its services and products in the United States and international emphasis in countries like European and Asia-Pacific regions. The Company operates in two operating segments; Sequenom Laboratories and Sequenom Bioscience. Sequenom Laboratories provides molecular based, laboratory developed tests, or LDTs, with a focus principally on prenatal diseases and conditions and ophthalmological diseases and conditions. Sequenom Bioscience provides technology and research tools for genetic analysis and applications in translational research, clinical research, pharmacogenomics, oncology, and agricultural genomics. The Company's competitors include; Ariosa Diagnostics, Inc., Beijing Genomics Institute, Cellscape Corp., Celula Inc., Ikonysis, Inc., Kellbenx, Inc., Laboratory Corporation of America Holdings, Inc., Natera, Perkin Elmer, Inc., Quest Laboratories, Verinata and others. Its patent portfolio, including in-licensed patent rights, includes approximately 638 issued or allowed patents in the United States and other industrial nations throughout the world. Its prenatal diagnostic patent portfolio includes exclusive rights to numerous in-licensed issued patents. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of such materials and chemicals, as well as certain waste products.
» More Articles for SQNM

Headlines

Articles On GuruFocus.com
Insiders Are Selling Dave & Buster's Entertainment and Buying Twinlab Oct 09 2015 
Context Capital Management's Top Buys in Q2 2015 Jul 15 2015 
GuruFocus 5-year lows: Anworth Mortgage Asset Corporation, Contango Oil & Gas Company, Dendreon Corp Sep 29 2013 
Weekly Three-Year Low Highlights: NS, MCRL, TITN, SQNM Sep 24 2013 
5 Year Lows: Anworth Mortgage Asset Corporation, Cantago Oil & Gas Company, Sequenom and North Ameri Sep 22 2013 
Gurus Hold Five-Year Lows in Biotech, Utilities Sep 20 2013 
Weekly CFO Buys Highlight: PTSX, MTG, IRDM, SQNM, FNFG, LF Aug 13 2012 
Sequenom Inc. CEO Harry Hixson Bought 50,000 Shares Aug 03 2012 
Sequenom Inc. Reports Operating Results (10-Q) Aug 05 2010 
Sequenom Inc. Reports Operating Results (10-Q) May 07 2010 

More From Other Websites
Sequenom Schedules First Quarter Results Conference Call for May 4, 2016 Apr 25 2016
SEQUENOM INC Files SEC form 8-K/A, Costs Associated with Exit or Disposal Activities, Other Events,... Apr 22 2016
Sequenom Completes Consolidation of North Carolina Operations Apr 19 2016
Sequenom Completes Consolidation of North Carolina Operations Apr 19 2016
Sequenom Strengthens Executive Team with New Vice President of Sales Apr 12 2016
Sequenom Strengthens Executive Team with New Vice President of Sales Apr 12 2016
Sequenom Announces In-Network Contracts with Anthem Blue Cross and Blue Shield Plans for... Mar 23 2016
Sequenom Announces In-Network Contracts with Anthem Blue Cross and Blue Shield Plans for... Mar 23 2016
Sequenom Files Petition With the Supreme Court of the United States Requesting Review Of Decision On... Mar 21 2016
Sequenom Files Petition With the Supreme Court of the United States Requesting Review Of Decision On... Mar 21 2016
Four Biotechs To Consider On Intermediate Bottom, Trend Change Signal Mar 14 2016
SEQUENOM INC Financials Mar 10 2016
Sequenom upgraded by Ladenburg Thalmann Mar 03 2016
SEQUENOM INC Files SEC form 8-K, Results of Operations and Financial Condition Mar 03 2016
SEQUENOM INC Files SEC form 10-K, Annual Report Mar 03 2016
Edited Transcript of SQNM earnings conference call or presentation 2-Mar-16 10:00pm GMT Mar 02 2016
Sequenom Announces Contract with Anthem BlueCross Mar 02 2016
Sequenom reports 4Q loss Mar 02 2016
Sequenom reports 4Q loss Mar 02 2016
Sequenom, Inc. Reports 2015 Financial Results Mar 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK